252 related articles for article (PubMed ID: 24375389)
1. Emerging evidence for CHFR as a cancer biomarker: from tumor biology to precision medicine.
Derks S; Cleven AH; Melotte V; Smits KM; Brandes JC; Azad N; van Criekinge W; de Bruïne AP; Herman JG; van Engeland M
Cancer Metastasis Rev; 2014 Mar; 33(1):161-71. PubMed ID: 24375389
[TBL] [Abstract][Full Text] [Related]
2. A phase 2 trial of gemcitabine and docetaxel in patients with metastatic colorectal adenocarcinoma with methylated checkpoint with forkhead and ring finger domain promoter and/or microsatellite instability phenotype.
Baretti M; Karunasena E; Zahurak M; Walker R; Zhao Y; Pisanic TR; Wang TH; Greten TF; Duffy AG; Gootjes E; Meijer G; Verheul HMW; Ahuja N; Herman JG; Azad NS
Clin Transl Sci; 2021 May; 14(3):954-963. PubMed ID: 33811727
[TBL] [Abstract][Full Text] [Related]
3. Methylation-independent CHFR expression is a potential biomarker affecting prognosis in acute myeloid leukemia.
Zhou JD; Zhang TJ; Li XX; Ma JC; Guo H; Wen XM; Yao DM; Zhang W; Lin J; Qian J
J Cell Physiol; 2018 Jun; 233(6):4707-4714. PubMed ID: 29115660
[TBL] [Abstract][Full Text] [Related]
4. CHFR-Promoter-Methylation Status Is Predictive of Response to Irinotecan-based Systemic Chemotherapy in Advanced Colorectal Cancer.
Hagiwara T; Sugimoto K; Momose H; Irie T; Honjo K; Okazawa YU; Kawai M; Kawano S; Munakata S; Takahashi M; Kojima Y; Serizawa N; Nagahara A; Hoffman RM; Brock MV; Sakamoto K
Anticancer Res; 2022 Feb; 42(2):697-707. PubMed ID: 35093868
[TBL] [Abstract][Full Text] [Related]
5. CHFR promoter hypermethylation and reduced CHFR mRNA expression in ovarian cancer.
Gao Y; Lou G; Zhang GM; Sun XW; Ma YY; Yang YM; Liu G
Int J Biol Markers; 2009; 24(2):83-9. PubMed ID: 19634111
[TBL] [Abstract][Full Text] [Related]
6. Promoter methylation of CHFR gene in gastric carcinoma tissues detected using two methods.
Cheng ZD; Hu SL; Sun YB; Xu WP; Shen G; Kong XY
Chin J Cancer; 2010 Feb; 29(2):163-6. PubMed ID: 20109344
[TBL] [Abstract][Full Text] [Related]
7. CHFR protein expression predicts outcomes to taxane-based first line therapy in metastatic NSCLC.
Pillai RN; Brodie SA; Sica GL; Shaojin Y; Li G; Nickleach DC; Yuan L; Varma VA; Bonta D; Herman JG; Brock MV; Ribeiro MJ; Ramalingam SS; Owonikoko TK; Khuri FR; Brandes JC
Clin Cancer Res; 2013 Mar; 19(6):1603-11. PubMed ID: 23386692
[TBL] [Abstract][Full Text] [Related]
8. Methylation of gene CHFR promoter in acute leukemia cells.
Gong H; Liu W; Zhou J; Xu H
J Huazhong Univ Sci Technolog Med Sci; 2005; 25(3):240-2. PubMed ID: 16201259
[TBL] [Abstract][Full Text] [Related]
9. Association of CHFR Promoter Methylation with Treatment Outcomes of Irinotecan-Based Chemotherapy in Metastatic Colorectal Cancer.
Cha Y; Kim SY; Yeo HY; Baek JY; Choi MK; Jung KH; Dong SM; Chang HJ
Neoplasia; 2019 Jan; 21(1):146-155. PubMed ID: 30562637
[TBL] [Abstract][Full Text] [Related]
10. CHFR: a key checkpoint component implicated in a wide range of cancers.
Sanbhnani S; Yeong FM
Cell Mol Life Sci; 2012 May; 69(10):1669-87. PubMed ID: 22159584
[TBL] [Abstract][Full Text] [Related]
11. Aberrant promoter hypermethylation of the CHFR gene in oral squamous cell carcinomas.
Baba S; Hara A; Kato K; Long NK; Hatano Y; Kimura M; Okano Y; Yamada Y; Shibata T
Oncol Rep; 2009 Nov; 22(5):1173-9. PubMed ID: 19787237
[TBL] [Abstract][Full Text] [Related]
12. Promoter hypermethylation of the Chfr gene in neoplastic and non-neoplastic gastric epithelia.
Honda T; Tamura G; Waki T; Kawata S; Nishizuka S; Motoyama T
Br J Cancer; 2004 May; 90(10):2013-6. PubMed ID: 15138487
[TBL] [Abstract][Full Text] [Related]
13. Checkpoint with forkhead-associated and ring finger promoter hypermethylation correlates with microsatellite instability in gastric cancer.
Oki E; Zhao Y; Yoshida R; Masuda T; Ando K; Sugiyama M; Tokunaga E; Morita M; Kakeji Y; Maehara Y
World J Gastroenterol; 2009 May; 15(20):2520-5. PubMed ID: 19469003
[TBL] [Abstract][Full Text] [Related]
14. Epigenetic inactivation of the CHFR gene in cervical cancer contributes to sensitivity to taxanes.
Banno K; Yanokura M; Kawaguchi M; Kuwabara Y; Akiyoshi J; Kobayashi Y; Iwata T; Hirasawa A; Fujii T; Susumu N; Tsukazaki K; Aoki D
Int J Oncol; 2007 Oct; 31(4):713-20. PubMed ID: 17786301
[TBL] [Abstract][Full Text] [Related]
15. Frequent hypermethylation of the 5' CpG island of the mitotic stress checkpoint gene Chfr in colorectal and non-small cell lung cancer.
Corn PG; Summers MK; Fogt F; Virmani AK; Gazdar AF; Halazonetis TD; El-Deiry WS
Carcinogenesis; 2003 Jan; 24(1):47-51. PubMed ID: 12538348
[TBL] [Abstract][Full Text] [Related]
16. Epigenetic inactivation of CHFR in human tumors.
Toyota M; Sasaki Y; Satoh A; Ogi K; Kikuchi T; Suzuki H; Mita H; Tanaka N; Itoh F; Issa JP; Jair KW; Schuebel KE; Imai K; Tokino T
Proc Natl Acad Sci U S A; 2003 Jun; 100(13):7818-23. PubMed ID: 12810945
[TBL] [Abstract][Full Text] [Related]
17. Epigenetic inactivation of CHFR in nasopharyngeal carcinoma through promoter methylation.
Cheung HW; Ching YP; Nicholls JM; Ling MT; Wong YC; Hui N; Cheung A; Tsao SW; Wang Q; Yeun PW; Lo KW; Jin DY; Wang X
Mol Carcinog; 2005 Aug; 43(4):237-45. PubMed ID: 15937956
[TBL] [Abstract][Full Text] [Related]
18. CHFR silencing or microsatellite instability is associated with increased antitumor activity of docetaxel or gemcitabine in colorectal cancer.
Pelosof L; Yerram SR; Ahuja N; Delmas A; Danilova L; Herman JG; Azad NS
Int J Cancer; 2014 Feb; 134(3):596-605. PubMed ID: 23873170
[TBL] [Abstract][Full Text] [Related]
19. Predictive value of CHFR and MLH1 methylation in human gastric cancer.
Li Y; Yang Y; Lu Y; Herman JG; Brock MV; Zhao P; Guo M
Gastric Cancer; 2015 Apr; 18(2):280-7. PubMed ID: 24748501
[TBL] [Abstract][Full Text] [Related]
20. Aberrant gene methylation in the peritoneal fluid is a risk factor predicting peritoneal recurrence in gastric cancer.
Hiraki M; Kitajima Y; Sato S; Nakamura J; Hashiguchi K; Noshiro H; Miyazaki K
World J Gastroenterol; 2010 Jan; 16(3):330-8. PubMed ID: 20082478
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]